Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerinetide in Acute Ischemic Stroke Undergoing Thrombectomy
NCT02930018Phase 3Completed
- Sponsor
- NoNO Inc.
- Start
- Mar 2017
- Primary completion
- Nov 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of nerinetide in ischemic stroke, sponsored by NoNO Inc. Primary endpoint: Number of Subjects With mRS Score of 0 to 2 at 90 days. Started Mar 2017; status: completed.
02
Drugs
nerinetide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02930018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930018.